Methods and compositions relating to proteasome inhibitor resistance
In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating the level of expression or activity of a subunit of the 19S proteasome in the cell. In some aspects, cells in which the level of a 19S subunit is modulated, e.g., reduced, are provided. In some aspects, methods of identifying agents that reduce proteasome inhibitor resistance are provided. In some aspects, methods of classifying cancers according to predicted proteasome inhibitor resistance are provided. In some aspects, methods of killing or inhibiting proliferation of cancer cells, e.g., proteasome inhibitor resistant cancer cells, are provided. In some aspects, methods of treating cancer, e.g., proteasome inhibitor resistant cancer, are provided.
1. A method of killing or inhibiting proliferation of a cancer cell comprising: contacting the cancer cell with (a) a BCL2 family inhibitor and (b) a proteasome inhibitor; wherein the method comprises determining that the cancer cell has reduced expression of at least one 19S proteasome subunit prior to contacting the cancer cell with the BCL2 family inhibitor and the proteasome inhibitor.
2. The method of claim 1 , wherein the proteasome inhibitor is bortezomib, carfilzomib, oprozomib, ixazomib, or an analog of any of these.
3. The method of claim 1 , wherein the cancer cell is a proteasome inhibitor resistant cancer cell.
4. The method of claim 1 , wherein the cancer cell is a proteasome inhibitor resistant cancer cell that has reduced expression of at least one 19S proteasome subunit.
5. The method of claim 1 , wherein the method comprises determining that the cancer cell has reduced expression of PSMD5, PSMD1, PSMC6, PSMD10, PSMD14, or PSMD6.
6. The method of claim 1 , wherein the cancer cell is a blood cancer cell.
7. A method of treating a subject in need of treatment for cancer comprising: administering a BCL2 family inhibitor to the subject, wherein the cancer has reduced expression of at least one 19S proteasome subunit; and wherein the method comprises determining that the cancer has reduced expression of at least one 19S proteasome subunit prior to administering the BCL2 family inhibitor to the subject.
8. The method of claim 7 , wherein the method further comprises administering a proteasome inhibitor to the subject.
9. The method of claim 8 , wherein the proteasome inhibitor is bortezomib, carfilzomib, oprozomib, ixazomib, or an analog of any of these.
10. The method of claim 7 , wherein the cancer has reduced expression of at least one 19S proteasome subunit.
11. The method of claim 7 , wherein the method comprises determining that the cancer has reduced expression of PSMD5, PSMD1, PSMC6, PSMD10, PSMD14, or PSMD6.
12. The method of claim 7 , wherein the cancer is a blood cancer.